Traws Pharma Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Traws Pharma kazanç ve gelirinin sırasıyla yıllık 21.5% ve 65% oranında artması tahmin edilirken, EPS'nin yıllık 42% oranında büyümesi bekleniyor.

Anahtar bilgiler

21.5%

Kazanç büyüme oranı

42.04%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	14.9%
Gelir büyüme oranı	65.0%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	22 Jun 2026

Gelecekteki son büyüme güncellemeleri

Recent updates

Anlatı Güncellemesi • Jun 26

TRAW: Influenza Setback Will Shift Focus Toward Broad Antiviral Pipeline Potential

Analysts cut their price target on Traws Pharma stock to $1 from $8, reflecting reduced confidence in the near term after the deferral of the tivoxavir marboxil Phase 2a influenza challenge study and what they describe as lower visibility on the company's next potential value driver. What’s in the News for Traws Pharma Traws Pharma is preparing an updated toxicology data package for tivoxavir marboxil to address information requests from the United Kingdom’s Medicines and Healthcare Products Regulatory Agency, with resubmission planned in the third quarter of 2026.

Yeni Anlatı • Apr 30

Pandemic Preparedness And Once Monthly Oral Flu Prophylaxis Will Transform This Antiviral Opportunity

Catalysts About Traws Pharma Traws Pharma is a biotechnology company focused on developing next generation antiviral treatments and prophylactic agents for influenza. What are the underlying business or industry changes driving this perspective?

Yeni Anlatı • Apr 16

Regulatory And Funding Risks Around Influenza Catalyst Will Eventually Support A Healthier Outlook

Catalysts About Traws Pharma Traws Pharma is a clinical stage company focused on developing next generation antiviral treatments and prophylactic therapies for influenza. What are the underlying business or industry changes driving this perspective?

Analiz Makalesi • Mar 09

We're Keeping An Eye On Onconova Therapeutics' (NASDAQ:ONTX) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analiz Makalesi • Apr 22

Here's Why We're Watching Onconova Therapeutics' (NASDAQ:ONTX) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Analiz Makalesi • Jul 27

Onconova Therapeutics (NASDAQ:ONTX) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Analiz Makalesi • Mar 21

Will Onconova Therapeutics (NASDAQ:ONTX) Spend Its Cash Wisely?

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Analiz Makalesi • Dec 06

Companies Like Onconova Therapeutics (NASDAQ:ONTX) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Kazanç ve Gelir Büyüme Tahminleri

NasdaqCM:TRAW - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2028	N/A	-21	-39	-17	1
12/31/2027	N/A	-24	-36	-14	2
12/31/2026	N/A	-21	-47	-19	2
3/31/2026	3	-14	-18	-15	N/A
12/31/2025	3	7	-21	-18	N/A
9/30/2025	3	-9	-22	-19	N/A
6/30/2025	3	-5	-27	-27	N/A
3/31/2025	0	-26	-31	-31	N/A
12/31/2024	0	-55	-30	-30	N/A
9/30/2024	0	-37	-30	-30	N/A
6/30/2024	0	-41	-23	-23	N/A
3/31/2024	0	-27	-18	-18	N/A
12/31/2023	0	-19	-18	-18	N/A
9/30/2023	0	-20	-17	-17	N/A
6/30/2023	0	-21	-17	-17	N/A
3/31/2023	0	-21	-17	-17	N/A
12/31/2022	0	-19	-16	-16	N/A
9/30/2022	0	-17	-17	-17	N/A
6/30/2022	0	-15	-17	-17	N/A
3/31/2022	0	-16	-17	-17	N/A
12/31/2021	0	-16	-19	-19	N/A
9/30/2021	0	-19	-21	-21	N/A
6/30/2021	0	-22	-22	-22	N/A
3/31/2021	0	-25	-23	-23	N/A
12/31/2020	0	-25	-23	-23	N/A
9/30/2020	0	-24	-23	-23	N/A
6/30/2020	0	-23	-21	-21	N/A
3/31/2020	2	-19	-21	-21	N/A
12/31/2019	2	-22	N/A	-21	N/A
9/30/2019	2	-21	N/A	-21	N/A
6/30/2019	2	-22	N/A	-24	N/A
3/31/2019	1	-23	N/A	-24	N/A
12/31/2018	1	-21	N/A	-23	N/A
9/30/2018	1	-21	N/A	-22	N/A
6/30/2018	1	-23	N/A	-22	N/A
3/31/2018	1	-21	N/A	-23	N/A
12/31/2017	1	-24	N/A	-24	N/A
9/30/2017	1	-23	N/A	-24	N/A
6/30/2017	2	-18	N/A	-19	N/A
3/31/2017	4	-21	N/A	-17	N/A
12/31/2016	6	-20	N/A	-16	N/A
9/30/2016	15	-11	N/A	-16	N/A
6/30/2016	15	-15	N/A	-22	N/A
3/31/2016	13	-19	N/A	-26	N/A
12/31/2015	11	-24	N/A	-31	N/A
9/30/2015	2	-41	N/A	-40	N/A
6/30/2015	0	-50	N/A	-46	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: TRAW önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: TRAW önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: TRAW önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: TRAW gelecek yıl gelir elde edemeyeceği tahmin ediliyor.

Yüksek Büyüme Geliri: TRAW gelecek yıl gelir elde edemeyeceği tahmin ediliyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: TRAW 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Büyüyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/06/29 08:13
Gün Sonu Hisse Fiyatı	2026/06/29 00:00
Kazançlar	2026/03/31
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları GitHub sayfamızda mevcuttur; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Traws Pharma, Inc. 10 Bu analistlerden 2, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Kimberly Lee	Brean Capital Historical (Janney Montgomery)
Michael Thomas Cooper	Edison Investment Research
Etzer Darout	Guggenheim Securities, LLC

Traws Pharma Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Price target decreased by 22% to US$6.50

Consensus revenue estimates decrease by 19%, EPS upgraded

Consensus EPS estimates upgraded to US$0.97 loss

Consensus revenue estimates fall by 13%

Consensus forecasts updated

Price target decreased to US$8.67

Recent updates

TRAW: Influenza Setback Will Shift Focus Toward Broad Antiviral Pipeline Potential

Traws Pharma Provides Updated Guidance on Influenza Prophylaxis Program

Traws Pharma Provides Regulatory Update on Influenza Program

Traws Pharma, Inc., Annual General Meeting, Jul 08, 2026

Pandemic Preparedness And Once Monthly Oral Flu Prophylaxis Will Transform This Antiviral Opportunity

Traws Pharma, Inc. announced that it expects to receive $10 million in funding from Sirenia Capital Management LP

Regulatory And Funding Risks Around Influenza Catalyst Will Eventually Support A Healthier Outlook

Traws Pharma, Inc. announced delayed annual 10-K filing

Traws Pharma, Inc. Completes Analysis of Ratutrelvir Clinical Study in Paxlovid-Eligible and Ineligible Covid-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as A Prophylactic Treatment for Seasonal Influenza

Traws Pharma Completes Enrollment of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients; Announces Plans for Added Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza

Traws Pharma Files Tivoxavir Marboxil Investigational New Drug Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in Paxlovid-19 Patients

Traws Pharma, Inc. Reports Positive Interim Clinical Data with Ratutrelvir Versus Paxlovid™?, Shows Activity in Paxlovid-Ineligible COVID-19 Patients

Expert Systems Inc. Supports Traws Pharma Phase 2 Clinical Studies of Ratutrelvir

Traws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025

Traws Pharma, Inc., Annual General Meeting, Nov 21, 2025

Traws Pharma, Inc. Appoints John Leaman to Its Board of Directors as an Independent Director, Effective October 1, 2025

Traws Pharma, Inc. Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025

Traws Pharma, Inc. to Report Q2, 2025 Results on Aug 14, 2025

Traws Pharma Advances Antiviral Pipeline with Multiple Regulatory Submissions

Traws Pharma Announces Receipt of FDA Guidance on Tivoxavir Marboxil and Reports Plans for Pursuing Stockpiling for Pandemic Preparedness

Traws Pharma, Inc. Announces CEO Changes

Traws Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $5.5142 million.

Traws Pharma Reports Positive Results from an Accepted Bird Flu Model for Anti-Viral Candidate, Tivoxavir Marboxil

Traws Pharma Regains Compliance with Nasdaq Minimum Stockholders’ Equity Requirement

Traws Pharma Inc. Announces CFO Changes

Traws Pharma Announces Completion of Phase I Studies with Tivoxavir Marboxil, a Single Dose Oral Investigational Drug for the Treatment and Prevention of H5N1 Bird Flu

Expert Systems and Traws Pharma Report Breakthrough in H5N1Bird Flu Antiviral Program

Traws Pharma, Inc. announced that it expects to receive $72.6 million in funding

Traws Pharma, Inc. Announces Progress in Developing Tivoxavir Marboxil for H5N1 Bird Flu

Traws Pharma Receives Non-Compliance Letter from Nasdaq Regarding Non-Compliance with the Minimum $2.5 Million Stockholders’ Equity Requirement under Nasdaq Listing Rule 5550(b)(1)

Traws Pharma, Inc., Annual General Meeting, Oct 31, 2024

Traws Pharma, Inc. Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil

Traws Pharma, Inc. Announces Positive Topline Phase 1 Results for Covid Candidate, Ratutrelvir, an Oral Mpro Inhibitor

Nasdaq Determines to Delist Traws Pharma's Securities

Traws Pharma, Inc. Announces Board Changes

Traws Pharma Receives Letter from The Nasdaq Capital Market Due to Non-Compliance with the Minimum Stockholders’ Equity Requirement for Continued Listing on the Nasdaq Capital Market

Traws Pharma, Inc. announced delayed 10-Q filing

Traws Pharma, Inc. to Report Q2, 2024 Results on Aug 15, 2024

Price target decreased by 22% to US$6.50

New minor risk - Shareholder dilution

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy

High number of new directors

Consensus revenue estimates decrease by 19%, EPS upgraded

Traws Pharma, Inc. Announces Chief Executive Office Changes

Traws Pharma, Inc. Announces Board Changes

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Onconova Therapeutics, Inc and Trawsfynydd Therapeutics, Inc. Announce Management Appointments for the Combined Company Traws Pharma, Inc

We're Keeping An Eye On Onconova Therapeutics' (NASDAQ:ONTX) Cash Burn Rate

Onconova TherapeuticsNarazaciclib Ash Poster Highlights Activity in Treatment Resistant Mantle Cell Lymphoma

Onconova Therapeutics’ Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i’s

Consensus EPS estimates upgraded to US$0.97 loss

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Onconova Therapeutics, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Onconova Therapeutics, Inc. Appoints Victor Moyo as Chief Medical Officer

Onconova Therapeutics Receives A Letter from the Nasdaq Capital Market Regarding Minimum Bid Price Requirement

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Onconova Therapeutics, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Onconova Therapeutics, Inc. Presents Preclinical Data on Narazaciclib at the 17Th International Conference on Malignant Lymphoma

Onconova Therapeutics, Inc., Annual General Meeting, Jul 21, 2023

Onconova Therapeutics Announces Dosing of First Participant in Investigator-Sponsored Phase 2 Trial of Rigosertib Plus Pembrolizumab in Metastatic Melanoma Patients Refractory to Immune Checkpoint Blockade

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Onconova Therapeutics Doses First Patient in Phase 1/2a Trial of Narazaciclib Combined with Letrozole in Endometrial Cancer

Onconova Therapeutics, Inc. to Report Q1, 2023 Results on May 15, 2023

Here's Why We're Watching Onconova Therapeutics' (NASDAQ:ONTX) Cash Burn Situation

Consensus revenue estimates fall by 13%

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Onconova Therapeutics, Inc. Announces Additional Clinical Data Demonstrating Rigosertib’s Monotherapy Activity in RDEB-Associated Squamous Cell Carcinoma

Insufficient new directors